• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pear Therapeutics to Participate in Citi's BioTech C-Suite Virtual Fireside Chat Series

    1/17/23 8:00:00 AM ET
    $PEAR
    Computer Software: Prepackaged Software
    Technology
    Get the next $PEAR alert in real time by email

    Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi's BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:00 a.m. ET. Corey McCann, M.D., Ph.D., President and CEO, will participate in the Citi analyst-hosted fireside chat to discuss Pear's progress on market access.

    Citi hosted events are intended for prospective and existing Citi clients only. To listen to the live event, please contact your Citi representative with interest.

    About Pear Therapeutics

    Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas., including the first three PDTs with disease treatment claims from the FDA. Pear's product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA's traditional 510(k) pathway while simultaneously reviewed through FDA's Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005429/en/

    Get the next $PEAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEAR

    DatePrice TargetRatingAnalyst
    1/26/2022$5.00Neutral
    B of A Securities
    1/20/2022$11.00Outperform
    Credit Suisse
    1/3/2022$12.00Buy
    BTIG Research
    12/29/2021$13.00Buy
    Citigroup
    12/22/2021$16.00Buy
    Chardan Capital
    12/16/2021Outperform
    Cowen & Co.
    More analyst ratings